Encoded Therapeutics
Develops precision gene therapies for severe genetic disorders.
Company facts
- Founded
- 2014
- Employees
- 164
- Headquarters
- United States
- CEO
- Kartik Ramamoorthi, Ph.D.
- Type
- Private
- Funding
- Series D · $135M · 2020
About
Encoded Therapeutics is committed to revolutionizing the treatment of pediatric central nervous system (CNS) disorders through the development of innovative genetic medicines. Founded in 2014, the company's goal is to translate next-generation science into transformative therapies that address the root causes of debilitating disorders affecting children. Encoded’s cutting-edge platform is designed to enable the creation of disease-modifying gene therapies that can offer potentially long-lasting benefits. At the core of Encoded’s mission is a relentless focus on patients. The company fosters a culture of creativity and exploration, understanding that diverse voices lead to diverse ideas and ultimately revolutionary treatment options. Their approach utilizes novel gene therapy methods that enhance gene specificity and cell selectivity, aimed at overcoming challenges faced by first-generation therapies. By prioritizing innovation in gene therapy, Encoded Therapeutics is ideally positioned to address the unique needs of patients suffering from conditions such as Dravet Syndrome and to deliver hope and improved health outcomes to families.